Pharmaceuticals
Commercializing and developing pharmaceuticals addressing large unmet needs
Improving the lives of people suffering from mental illness and substance use disorders
Developing improved pharmaceuticals based on innovative drug delivery technologies
Providing evidence-based digital therapies to improve treatment outcomes
What we do
Digital Therapeutics
Product portfolio of scientifically proven digital therapies
Mental illness & substance use disorders
Focusing on areas of great human suffering with wider societal implications
We Care
Shedding light on lives affected by addiction and the road to recovery
Our mission for our blog platform on which we share the stories and insights from individuals coping with addiction, recovery and mental health.
Key News
APRIL 13, 2021
Report from the Annual General Meeting
MARCH 23, 2021
Publication of 2020 Annual Report
MARCH 17, 2021
ZUBSOLV´s patent portfolio continues to strengthen
Our history
Strong history paving the way for the future. Learn more about our key milestones since we where founded in Uppsala, Sweden, in 1995.
Orexo Social
@OrexoABpubl
12 April 2021
THIS IS BEYOND. Such an inspiring and hopeful story our colleague PSyD Gery-Lynn Utter brings to her important work… https://t.co/LqjD2va8er
@OrexoABpubl
8 April 2021
To avoid being captured in the vicious circle of #addiction there is a need of counselling support to cope with AUD… https://t.co/wcpUZLvlap
@OrexoABpubl
7 April 2021
Ethypharm acquires the rights to deprexis & vorvida in 4 European countries from our partner @GAIA_COM. Yet another… https://t.co/USDN34EMMN
News Flow
Financial Snapshot
Group net revenues
663.6 MSEK
LTM1
Group EBITDA
19.0 MSEK
LTM1
US Pharma segment EBIT
331.2 MSEK
LTM1
Cash position
505.3 MSEK
Q4 2020
1 Last Twelve Months, Q120-Q420, for more information about financial development Link